As antibiotics lose their power to treat some forms of TB, interest in the antibacterial powers of curdlan is rising.
Academic rigor, journalistic flair
Articles on Pharmaceuticals
Displaying 21 - 40 of 203 articles
Believe it or not, medication names are intended to be easy to remember and descriptive of the function they serve in the body.
From tablets and patches to ointments and infusions, the best way to deliver a drug is the one that gets the right amount to the right place.
As long as industrial policies in Nigeria are introduced only as a crisis response, import restrictions will continue to be their focus.
About 1 in 4 Americans with diabetes who need insulin struggle to pay for this lifesaving drug.
An infectious disease doctor discusses the use, benefits and availability of a drug to prevent severe COVID-19.
While technological advancements have quickened the drug discovery process, some chemical compounds remain a common thorn in a researcher’s side.
Drug repurposing can redeem failed treatments and squeeze out new uses from others. But many pharmaceutical companies are hesitant to retool existing drugs without a high return on investment.
Changes in the latest federal budget will mostly affect people who need multiple medicines throughout the year, perhaps for chronic disease. But there are other ways to reduce drug costs.
It’s easy to blame COVID. But Australia has suffered medicine shortages for years. The pandemic has only highlighted the problem. Here’s what we could do to better avoid shortages in the first place.
Drug development is a long and costly process that often ends in failure. Improving the way potential drug candidates are optimized could help boost success rates.
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
We’ve made a few mistakes in the past two years, when it comes to developing COVID drugs. Some were obvious and could have easily been avoided.
South Africa has a stringent pharmaceutical regulatory framework. But this framework is not backed by a strong implementation strategy.
Paxlovid is one potential COVID drug for use at home. The idea is these can potentially be prescribed at the first sign of infection to prevent serious illness and death.
A new study suggests the market alone will not deter or punish pharmaceutical companies whose products turn out to have adverse effects after they have been approved.
Non-intoxicating cannabis products are safe and well tolerated by those who use them, so why not lower the clinical threshold for their manufacture and sale?
The path to using old drugs for COVID is full of potholes. So why are we using the same old flawed methods when we actually know what works?
Here’s how to make the learning process fun and safe.
Chemicals in drugs can be excreted unchanged, infiltrating waterways via sewage and effluent.
Top contributors
-
Professor and Director Academic Excellence, Macquarie University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Lecturer Pharmacy Practice, University of Sydney
-
Pharmacist and PhD Candidate, University of Sydney
-
HERA Program Director - Health Workforce Optimisation Centre for the Business & Economics of Health, The University of Queensland
-
Assistant Professor, Bond University
-
PhD Candidate, Swinburne University of Technology
-
Research associate, University of Pretoria
-
Research Fellow, Stellenbosch University
-
Lecturer in Accounting & Management, Lancaster University
-
ARC Future Fellow, Australian National University
-
Purple House Medical Advisor. Honorary ANU., Australian National University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics, Macquarie University
